Automated prediction of dosimetric eligibility for hypofractionated prostate radiotherapy

Clinical implementation of hypofractionated prostate radiotherapy (PROFIT trial, NCT003046759) represents an opportunity to significantly reduce the burden of treatment on the patient and clinic. However, efficacy was only demonstrated among the patient demographic who could meet the trial dose constraints and so it is necessary to emulate this triage step in clinical practice. The purpose of this study was to build a convenient tool to address the challenge of determining patient eligibility for hypofractionated treatment within the clinic. The tool was implemented within the Eclipse(TM) treatment planning system using the scripting environment. Prior to planning a new case, the script computes and displays in a plot the fractional overlap of rectal and bladder wall with the planning target volume. Radial decision boundaries separate the plot into three zones and the new case is then classified as “feasible”, “uncertain”, or “not feasible”. The radial decision boundaries were derived from a retrospective analysis of the overlap values and dosimetric eligibility of 150 patients with intermediate risk prostate cancer. Two‐fold cross validation with repetitions demonstrated an average prediction accuracy of over 90%. The tool has been integrated into our clinical planning workflow to enable early identification of the need for planning consults and rapid a‐priori determination of dosimetric eligibility for hypofractionated radiotherapy. The tool can be readily adopted by other centres since the underlying metrics can be evaluated without scripting if desired.